Joseph Meserve

1.3k total citations
16 papers, 384 citations indexed

About

Joseph Meserve is a scholar working on Epidemiology, Genetics and Surgery. According to data from OpenAlex, Joseph Meserve has authored 16 papers receiving a total of 384 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Epidemiology, 10 papers in Genetics and 6 papers in Surgery. Recurrent topics in Joseph Meserve's work include Microscopic Colitis (10 papers), Inflammatory Bowel Disease (10 papers) and Eosinophilic Esophagitis (3 papers). Joseph Meserve is often cited by papers focused on Microscopic Colitis (10 papers), Inflammatory Bowel Disease (10 papers) and Eosinophilic Esophagitis (3 papers). Joseph Meserve collaborates with scholars based in United States, Canada and Italy. Joseph Meserve's co-authors include Georges El Fakhri, Arkadiusz Sitek, Marcelo F. Di Carli, Sharmila Dorbala, Steven C. Moore, Siddharth Singh, Parambir S. Dulai, William J. Sandborn, Ariela Holmer and Vito Annese and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Gastroenterology.

In The Last Decade

Joseph Meserve

15 papers receiving 375 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joseph Meserve United States 8 188 92 88 82 64 16 384
M. Maher Ireland 9 169 0.9× 141 1.5× 157 1.8× 198 2.4× 67 1.0× 13 539
Evan Lehrman United States 10 110 0.6× 14 0.2× 31 0.4× 137 1.7× 29 0.5× 36 370
Miwa Morikawa Japan 12 127 0.7× 20 0.2× 80 0.9× 73 0.9× 14 0.2× 39 465
Dieter Grab Germany 13 129 0.7× 30 0.3× 37 0.4× 187 2.3× 41 0.6× 25 770
Paolo Cabassa Italy 13 101 0.5× 10 0.1× 144 1.6× 51 0.6× 71 1.1× 21 407
Kaiyan Li China 8 34 0.2× 12 0.1× 30 0.3× 54 0.7× 25 0.4× 33 261
David Beauvais France 10 22 0.1× 35 0.4× 48 0.5× 20 0.2× 32 0.5× 39 329
Gareth Horgan Ireland 6 24 0.1× 62 0.7× 51 0.6× 122 1.5× 16 0.3× 12 272
Dongsheng Zhang China 9 33 0.2× 17 0.2× 36 0.4× 118 1.4× 12 0.2× 32 285
Javzandulam Natsag Japan 12 88 0.5× 11 0.1× 66 0.8× 52 0.6× 12 0.2× 16 438

Countries citing papers authored by Joseph Meserve

Since Specialization
Citations

This map shows the geographic impact of Joseph Meserve's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Meserve with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Meserve more than expected).

Fields of papers citing papers by Joseph Meserve

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Meserve. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Meserve. The network helps show where Joseph Meserve may publish in the future.

Co-authorship network of co-authors of Joseph Meserve

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Meserve. A scholar is included among the top collaborators of Joseph Meserve based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Meserve. Joseph Meserve is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Meserve, Joseph, et al.. (2024). S2404 Congenital Portosystemic Shunt: A Rare Cause of Chronic Adult Abdominal Pain. The American Journal of Gastroenterology. 119(10S). S1714–S1714.
2.
Meserve, Joseph, et al.. (2023). Temporary Faecal Diversion for Refractory Perianal and/or Distal Colonic Crohn’s Disease in the Biologic Era: An Updated Systematic Review with Meta-analysis. Journal of Crohn s and Colitis. 18(3). 375–391. 10 indexed citations
3.
McCurdy, Jeffrey D., Joseph Meserve, Tim Ramsay, et al.. (2023). Development of an MRI-Based Prediction Model for Anti-TNF Treatment Failure in Perianal Crohn’s Disease: A Multicenter Study. Clinical Gastroenterology and Hepatology. 22(5). 1058–1066.e2. 6 indexed citations
4.
Meserve, Joseph, Wenhong Zhu, Gretchen Bandoli, et al.. (2021). Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases. Gastroenterology. 161(1). 107–115.e3. 20 indexed citations
5.
Meserve, Joseph, Christopher Ma, Parambir S. Dulai, Vipul Jairath, & Siddharth Singh. (2021). Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn’s Disease: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. 20(12). 2728–2740.e1. 35 indexed citations
6.
Meserve, Joseph & Parambir S. Dulai. (2020). Predicting Response to Vedolizumab in Inflammatory Bowel Disease. Frontiers in Medicine. 7. 76–76. 12 indexed citations
7.
Meserve, Joseph, Antonio Facciorusso, Ariela Holmer, et al.. (2020). Systematic review with meta‐analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre‐existing inflammatory bowel diseases. Alimentary Pharmacology & Therapeutics. 53(3). 374–382. 59 indexed citations
8.
Meserve, Joseph, et al.. (2020). Understanding Determinants of Patient Preferences Between Stool Tests and Colonoscopy for the Assessment of Disease Activity in Inflammatory Bowel Disease. Digestive Diseases and Sciences. 66(8). 2564–2569. 18 indexed citations
9.
Meserve, Joseph, et al.. (2019). In the absence of head-to-head trials, what do real world studies tell us about the comparative effectiveness of biologics in Crohn's disease. Best Practice & Research Clinical Gastroenterology. 38-39. 101619–101619. 3 indexed citations
10.
Meserve, Joseph, Parambir S. Dulai, Sunhee Park, et al.. (2017). Vedolizumab does not Increase the Risk of Enteric Infections as Compared to Infliximab: A Retrospective Cohort Study. Gastroenterology. 152(5). S109–S110. 1 indexed citations
11.
Dulai, Parambir S., Farhad Peerani, Neeraj Narula, et al.. (2016). Sa1889 Efficacy and Predictors of Outcomes of Vedolizumab for Crohn's Disease in Clinical Practice. Gastroenterology. 150(4). S393–S393. 1 indexed citations
13.
Peerani, Farhad, Neeraj Narula, Parambir S. Dulai, et al.. (2016). Sa1888 Efficacy and Predictors of Outcomes of Vedolizumab for Ulcerative Colitis in Clinical Practice. Gastroenterology. 150(4). S392–S393. 2 indexed citations
14.
Chaudrey, Khadija, Diana Whitehead, Parambir S. Dulai, et al.. (2016). Tu1908 Safety of Vedolizumab in Inflammatory Bowel Disease in a Multi-Center Real World Consortium. Gastroenterology. 150(4). S974–S974. 3 indexed citations
15.
Rimawi, Bassam H., Joseph Meserve, Ramzy H. Rimawi, Zaw Min, & John W. Gnann. (2015). Disseminated Herpes Simplex Virus with Fulminant Hepatitis. SHILAP Revista de lepidopterología. 2015. 1–4. 13 indexed citations
16.
Carli, Marcelo F. Di, Sharmila Dorbala, Joseph Meserve, et al.. (2007). Clinical Myocardial Perfusion PET/CT. Journal of Nuclear Medicine. 48(5). 783–793. 200 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026